Skip to main content

Hematologic cancers

News and opinion

29-04-2020 | AACR 2020 | News

Data shed light on severe outcome risk in cancer patients with COVID-19

Data presented at the 2020 AACR Virtual Annual Meeting I add to the growing body of evidence to suggest that people with cancer have more severe outcomes when infected with SARS-CoV-2 than those without cancer.

21-10-2019 | Lung cancer | News

BCG vaccination linked to reduced incidence of lung cancer

Receipt of the Bacillus Calmette-Guérin vaccine may reduce the risk for developing lung cancer, suggests a secondary analysis of a clinical trial conducted in American–Indian and Alaska Native populations.

18-03-2019 | Risk factors | News

Infertility linked to increased risk for multiple cancer types

Women with infertility have a significantly higher risk than those without for both hormonal and nonhormonal cancers, but the absolute risk in both groups is low, shows an analysis of US insurance claims data.

08-03-2019 | Guidelines | News

Consensus guidelines for management of comorbid rheumatoid arthritis, cancer examined

A systematic review of consensus recommendations for the management of rheumatoid arthritis in patients with cancer shows agreement in some areas, but highlights the need for further research into topics for which discrepancies exist.

11-01-2019 | Tyrosine kinase inhibitors | News

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

10-12-2018 | B-cell lymphoma | News

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

07-12-2018 | Chronic lymphocytic leukemia | News

Ibrutinib plus obinutuzumab more effective than chemoimmunotherapy in CLL

Combining ibrutinib rather than chlorambucil with obinutuzumab significantly improves progression-free survival in previously untreated patients with chronic lymphocytic leukemia, phase III study data show.

05-12-2018 | Diffuse large B-cell lymphoma | News

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

20-11-2018 | FDA | News

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

19-10-2018 | Follicular lymphoma | News

Post-induction PET predicts outcome in follicular lymphoma

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

17-10-2018 | Chronic lymphocytic leukemia | News

Duvelisib offers treatment alternative for patients with CLL/SLL

The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.

15-10-2018 | Acute lymphoblastic leukemia | Podcast | Audio

ALL and infection: Unpicking the connection

Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role (10:21).

05-10-2018 | Acute myeloid leukemia | News

Lomustine benefits older patients with favorable-, intermediate-risk AML

Adding lomustine to standard chemotherapy with idarubicin and cytarabine significantly improves survival in fit older patients with favorable- or intermediate-risk acute myeloid leukemia, phase III trial data show.

05-10-2018 | FDA | News

NGS test approved for ALL, multiple myeloma residual disease

The US FDA announcement is reported here

28-09-2018 | Hematologic cancers | News

In other news: Hematologic cancer focus

This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.

20-09-2018 | Hodgkin lymphoma | News

Hormonal biomarker shows ovarian toxicity of Hodgkin lymphoma treatment

Phase III trial data have highlighted the value of antimüllerian hormone as a biomarker of ovarian toxicity associated with different chemotherapy regimens for advanced Hodgkin lymphoma.

20-09-2018 | FDA | News

Hairy cell leukemia cytotoxin therapy approved by FDA

More information on this announcement here

19-09-2018 | Myelodysplastic syndrome | News

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

12-09-2018 | Pediatric leukemia | News

Levofloxacin reduces bacteremia during chemotherapy for childhood leukemia

Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.

Image Credits